Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2006-12-26
2006-12-26
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S001110, C424S001650, C424S009100
Reexamination Certificate
active
07153491
ABSTRACT:
This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
REFERENCES:
patent: 5506242 (1996-04-01), MacPherson et al.
patent: 5532359 (1996-07-01), Marsters et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5594006 (1997-01-01), Sakamoto et al.
patent: 5604102 (1997-02-01), McConnlogue et al.
patent: 5672598 (1997-09-01), De et al.
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 5721106 (1998-02-01), Maggio et al.
patent: 5734054 (1998-03-01), Dolle, III et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5843941 (1998-12-01), Marsters et al.
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6329163 (2001-12-01), Anderson et al.
patent: 6331408 (2001-12-01), Zaczek et al.
patent: 6737038 (2004-05-01), Zaczek et al.
patent: 6878363 (2005-04-01), Zaczek et al.
patent: 2005/0019255 (2005-01-01), Zaczek et al.
patent: 0276436 (1987-12-01), None
patent: 0606046 (1993-12-01), None
patent: 0652009 (1995-05-01), None
patent: WO 92/00374 (1992-01-01), None
patent: WO 92/06966 (1992-04-01), None
patent: WO-95/09838 (1995-04-01), None
patent: WO 95/22966 (1995-08-01), None
patent: WO 96/29313 (1996-09-01), None
patent: WO-98//38177 (1998-03-01), None
patent: WO 98/15828 (1998-04-01), None
patent: WO 98/22493 (1998-05-01), None
patent: WO-98/22494 (1998-05-01), None
patent: WO 98/28268 (1998-07-01), None
patent: WO 99/66934 (1999-12-01), None
patent: WO-99/67219 (1999-12-01), None
patent: WO-99/67220 (1999-12-01), None
patent: WO 99/67221 (1999-12-01), None
patent: WO 00/24392 (2000-05-01), None
patent: WO-00/28331 (2000-05-01), None
A. Ahmed et al.,FEBS Letters, (1984), vol. 174, pp. 76-79.
Arora et al.,J. Med. Chem., 30: p. 918 (1987).
P. Becket, M. J. Crimmin, M. H. Davis, and Z. Spavold,Synlett(1993), pp. 137-138.
Bock et al.,J. Med. Chem. 1993, 36, pp. 4276-4292.
Bock et al.,J. Org. Chem 1987, 52, pp. 3232-3239.
F. A. Carey and R. J. Sundberg, “Advanced Organic Chemistry, Part A,”New York: Plenum Press, 1990, pp. 304-305, 342-347, 475-479, 695-698.
Chumpradit et al., J. Med. Chem., 32: p. 1431 (1989).
Chumpradit et al., J. Med. Chem., 34: p. 877 (1991).
Ellis et al.,Aust. J. Chem., 26,: p. 907 (1973).
Evans, A et al. Org.Synth.68.p. 83-91 (1990).
Glenner and Wong,Biochem. Biophys. Res. Commun. 120; pp. 885-890.
Ghosh et al. JACS (2000) 122 pp. 3522-3523.
J. Higaki, D. Quon, Z. Zhong, B. Cordell, “Inhibition of beta-amyloid Formation identifies Proteolytic Precursors and Subcellular Site of Catabolism”, Neuron 14, pp. 651-659, 1995.
Jacobson and Reddy, Tetrahedron Letters, vol. 37, No. 46, pp. 8263-8266.
Kabalka et al., J. Label. Compound. Radiopharm., 19: p. 795 (1982).
A. S. Kende et al., Tetrahedron Lett. 1989, 30 (43), 5821-5824.
K. S. Kirshenbaum, K. B. Sharpless, J. Org. Chem. (1985), 50 (11), pp. 1979-1982.
P. Kocienski,Tetrahedron 1990, 46, pp. 1767-1782.
Koch et al. ,Chem. Ber., 124: p. 2091 (1991).
Levitan, D. and Greenwald, I.Nature,377, pp. 351-354,1995.
Lin et al.,PNAS(2000) 97: pp. 1456-1460.
Mach et al.,J. Med. Chem., 1993, 36, pp. 3707-3720.
McClure and Axt,Bioorganic&Medicinal Chemistry Letters, 8 (1998), pp. 143-146.
Merkushev,Synthesis, 923 (1988).
C. F. Nutaitis and M. W. Ledeboer,Org. Prep. Proced. Int. (1992), 24 (2), pp. 143-146.
Pratt et al.,Synlett, May 1998, p. 531.
M. P. Reddy and P. J. Voelker,Int. J. Pept. Protein Res. 1998, 31, pp. 345-348.
“Remington's Pharmeceutical Sciences,” 17thed. Mack Publishing Company, Easton, PA, 1985, p. 1418.
D. J. Selkoe, “Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease,”Annu. Rev. Cell. Biol., 1994, 10: pp. 373-403.
Seevers et al.,Chem. Rev., 82, p. 575 (1982).
Sherrill and Sugg,J. Org. Chem. 1995, 60, pp. 730-734.
Vassar et al.,Science1999 286: pp. 735-741.
D. A. Walsh, Synthesis, Sep. 1980, p. 677.
Wilbur et al., J. Label. Compound. Radiopharm., 1982 19: p. 1171.
Eckart et al, J. Org. Chem., 1986 51: p. 483-486.
Wolf, Chrisman, Fowler, Lambrecht, “Synthesis of Radiopharmaceuticals and Labeled Compounds Using Short-Lieved Isotopes,” in Radiopharmaceuticals and Labeled Compounds, vol. 1, 1973, pp. 345-381.
Book, M.Keen (ed) Receptor binding techniques methods in molecular Biology, vol. 106,Humana Press ,Totowa, New Jersay,1999.
Eckelman et al. J.Nucl. Med ,vol. 20(4) pp. 350-357 (1979).
T.W.Green and Wuts, Proptective Grups in organic Synthesis (Wiley 1991).
Tubis and Wolf, eds Radiopharmacy,Wiley-Interscience New York (1976) vol. 1 p. 345-381(1973).
Wilson et al. J.Org.Chem 51 4833 (1986).
U.S. Pharmacopia—The National Formulary 22ndRevision,Mack Printing Co.Easton, Pa 1990. “Radioactive Pharmaceuticals” relevent sections as per Index on p. 2049.
Book, A. Macowski Medical Imaging Systems ed.Prentice-Hall,Inc Englewood Cliffs NJ(1983).
E.I. Rogaev et al. Nature, vol. 376 pp. 774-778 (1995).
M. G. Natchus et al., “Design and synthesis of conformationally constrained MMP inhibitors,” Chemical Abstracts, vol. 129, No. 22, Nov. 30, 1998, abstract No. 290051p.
Olson Richard E.
Seiffert Dietmar A.
Thompson Lorin Andrew
Zaczek Robert
Bristol-Myers Squibb Pharma Company
Jones Dameron L.
Kelley Drye & Warren LLP
LandOfFree
Use of small molecule radioligands to discover inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of small molecule radioligands to discover inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of small molecule radioligands to discover inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3675837